Novartis Gets By With A Little Help From Its Hypertension Franchise
Executive Summary
Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call
You may also be interested in...
The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay
Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested